Improving symptom tracking for suspected head and neck cancer patients
EVolution of a patiEnt-REported Symptom-based Risk Stratification sySTem to Redesign the Suspected Head and Neck Cancer Referral Pathway (Phase 1)
This study is trying to improve how we track symptoms in patients who might have head and neck cancer to make sure they get the best care possible.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 165 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Royal Marsden NHS Foundation Trust Academic / other |
| Locations | 4 sites (Leeds and 3 other locations) |
| Trial ID | NCT05909020 on ClinicalTrials.gov |
What this trial studies
This study aims to enhance the pathway for patients suspected of having head and neck cancer by developing a patient-reported symptom-based risk stratification system. It involves optimizing a symptom inventory specifically for head and neck cancer and outlining the requirements for a clinical system to input these symptoms. The approach is observational and focuses on understanding the existing diagnostic pathways and the values of both patients and clinicians. The study will gather insights to ensure the language and information elicited are accessible and effective.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older who are referred through the suspected head and neck cancer pathway and have no prior history of the disease.
Not a fit: Patients who do not meet the inclusion criteria, such as those with a previous history of head and neck cancer, will not benefit from this study.
Why it matters
Potential benefit: If successful, this could lead to more accurate and timely diagnoses for patients suspected of having head and neck cancer.
How similar studies have performed: While this approach is innovative in its focus on patient-reported outcomes, similar studies have shown promise in improving diagnostic pathways in other cancer types.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Patients: * Adults ≥ 18 years referred via suspected HNC pathway without previous history of HNC * Participants willing and able to give informed consent for participation in the study. Clinicians: * Staff at participating sites involved in the diagnostic pathway for people with suspected HNC. Exclusion Criteria: * Individuals who do not meet the inclusion criteria.
Where this trial is running
Leeds and 3 other locations
- Leeds Teaching Hospitals NHS Trust — Leeds, United Kingdom (Not_yet_recruiting)
- Liverpool University Hospitals NHS Foundation Trust — Liverpool, United Kingdom (Recruiting)
- Luton & Dunstable University Hospital — Luton, United Kingdom (Recruiting)
- Oxford NHS Foundation Trust — Oxford, United Kingdom (Recruiting)
Study contacts
- Study coordinator: Sarah Webb
- Email: EVEREST-HN@rmh.nhs.uk
- Phone: 0208 915 6666
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.